Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Assets: 2021-2024

Historic Assets for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $580.6 million.

  • Kiniksa Pharmaceuticals International's Assets rose 28.28% to $712.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $712.3 million, marking a year-over-year increase of 28.28%. This contributed to the annual value of $580.6 million for FY2024, which is 10.30% up from last year.
  • As of FY2024, Kiniksa Pharmaceuticals International's Assets stood at $580.6 million, which was up 10.30% from $526.3 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's 5-year Assets high stood at $580.6 million for FY2024, and its period low was $232.8 million during FY2021.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Assets had a median value of $526.3 million in 2023 and averaged $522.2 million.
  • Data for Kiniksa Pharmaceuticals International's Assets shows a peak YoY skyrocketed of 97.45% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows Kiniksa Pharmaceuticals International's Assets stood at $232.8 million in 2021, then soared by 97.45% to $459.7 million in 2022, then increased by 14.50% to $526.3 million in 2023, then rose by 10.30% to $580.6 million in 2024.